AXIM Biotechnologies Releases Rapid NeuCovix Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests

SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announces the completion of a study highlighting the performance of NeuCovix, AXIM’s rapid test to measure levels of neutralizing anti-COVID-19 antibodies.

The NeuCovix test was compared to a gold standard pseudovirus-based test. NeuCovix accurately classified serum from patients who strongly neutralized SARS-CoV-2 and serum from patients who poorly neutralized the virus. Additionally, NeuCovix did not cross-react with serum from patients with seasonal respiratory infections including seasonal coronaviruses, suggesting that the test has 100 percent specificity for COVID-19. 

In contrast to current tests using live viruses, which are time-consuming, expensive and require trained personnel in a tightly controlled laboratory environment to measure neutralizing antibodies, NeuCovix is a portable, low cost, rapid point-of-care test that determines levels of neutralizing antibodies in approximately 10 minutes.

Since NeuCovix agrees with virus-based assays, it could be an effective and low-cost tool for monitoring large numbers of vaccine recipients for neutralizing antibodies. NeuCovix can also be used to measure levels of neutralizing antibodies in patients receiving hyperimmune globulin or convalescent plasma so that healthcare providers can decide on the proper dosing of neutralizing antibodies that correlates with favorable outcomes.

“We are extremely pleased with the initial test results that NeuCovix showed,” commented AXIM Biotech CEO John W. Huemoeller II. “The difference in time and money for blood centers and vaccine developers that our test delivers is staggering.”

“While we still have work to do for the EUA, our 10-minute point-of-care test is showing almost identical protective immune responses in plasma samples from patients with low titers and high titers as other more expensive and time-consuming lab tests,” said Sergei Svarovsky, Ph.D., MBA, Chief Scientific Officer of Sapphire Biotech, a wholly-owned subsidiary of AXIM Biotech.

NeuCovix^TM has not been approved by the FDA. 

About AXIM Biotechnologies
Founded in 2014, AXIM Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s NeuCovix^TM is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com.